


2 November 2022

ASX ANNOUNCEMENT

ImpediMed Reaches Milestone of 500,000 Patient Tests Performed with the SOZO Digital Health Platform

ImpediMed Limited (ASX:IPD) reached a milestone of 500,000 patient tests performed with the SOZO® Digital Health Platform. The Company called out this pending milestone in October on its recent Quarterly Investor Conference Call, held on 19 October 2022, and now confirms that it has been achieved.

With over 1,100 devices in use globally, including over 500 in the US Core Business¹, the pace of patient testing continues to accelerate with 100,000 patient tests performed in just the past six months. In comparison, the first 100,000 was achieved in 32 months. Product improvements, new clinical evidence, and comprehensive programs, such as the Lymphoedema Prevention Program, have all contributed to increased utilisation of SOZO by clinicians for the benefit of patients.



With the 500,000 tests comes over 1.5 billion data points now captured. Utilisation of this unique data set is only in its infancy, but the potential of the SOZO Digital Health Platform was recently demonstrated when Cleveland Clinic used historic data to produce two papers on the effectiveness of BIS in assessing sarcopenia. The data set will continue to get richer and more valuable as further applications are added, providing new insights into the course and care of a large number of chronic disease states.

¹ The **Core Business** refers to the commercialisation efforts from the Company's core strategic focus areas. To date, this primarily includes revenue from SOZO contracts in the Oncology market.

“Every time a patient is measured using SOZO, our bioimpedance spectroscopy technology delivers condition-specific metrics that inform medical decisions at the point-of-care,” stated Dave Anderson, Interim CEO and Director of ImpediMed.

“Reaching 500,000 patient tests is an important milestone and positive indicator of the future health of our business. Many lives have been dramatically improved by the reduction on lymphoedema as a result of this testing and I want to thank our team, our customers, our partners, and, most importantly, patients for their dedication to the advancement and adoption of SOZO to improve patient care,” he continued.

This announcement was approved for release by Interim CEO and Director, Dave Anderson.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit <https://www.impedimed.com/products/sozo/>.

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.